Category: Therapeutics

ADC Manufacturing: How Are the Contract Manufacturers Supporting the Growing Demand

Antibody Drug Conjugates (ADCs) known as the 21st Century Magic Bullets, have emerged as a promising class of targeted therapies being developed for the treatment of cancer. Two decades ago, in the year 2000, the domain witnessed the approval of first ADC known as Mylotarg®, by the US FDA.  This was followed by the successful

Digital Therapeutics: Key Concepts to Tackle COVID-19 Pandemic

Digital therapeutics are clinically validated applications / software / online programs that have demonstrated the capability to facilitate positive outcomes when used in the prevention / treatment / management of diseases / clinical conditions. These therapeutics are designed to engage patients in personalized treatment or disease prevention programs, through mediating behavioral or psychological modifications, providing

Autoinjectors: Increasing Demand for Self-Administration Devices

Over the last decade, autoinjectors have emerged as a promising therapeutic commodity for safe administration of parenteral therapies. Patients who suffer from chronic diseases, such as diabetes, rheumatoid arthritis and multiple sclerosis, often require frequent dosing of medication which poses significant inconvenience to them for visiting proper healthcare centers. Hence, autoinjector devices enable such patients

TPD: A Major Therapeutic Modality in the Coming Decade

The targeted protein degradation (TPD) approach is believed to possess the potential to unlock the undruggable proteome profile, which was traditionally considered to be inaccessible. Compared to conventional inhibition strategies, TPD offers several benefits, which include the opportunity to completely remove aberrant proteins and associated systemic malfunctions. As a result, TPD-based therapeutics have generated enthusiasm

Immune Checkpoint Inhibitors: Another Big Opportunity

There is an urgent unmet need for developing innovative and effective cancer therapeutics for the treatment of patients with late-stage and refractory cancer. Amidst the widespread initiatives to develop more targeted anti-cancer therapies, immune checkpoint inhibitors emerged as a highly specific and potent option to eradicate tumor cells with minimal side effects. Once the body

Cell Therapy Manufacturing: The $ 8 Billion+ Growth Opportunity

Cell Therapy Manufacturing market has gained significant attention in the overall biopharmaceutical industry. The personalized nature of these cell therapies options render them highly specific and, according to a number of clinical studies, safe and efficacious. Around 20 such therapies have been approved so far; recent approvals include Alofisel® (2018), YESCARTA® (2017) and Kymriah® (2017).

The Meteoric Rise of Digital Therapeutic, Monitoring and Diagnostic Solutions

Chronic disorders, such as diabetes, heart disease, obesity, mental health problems and insomnia, are considered to be the leading causes of death and disability across the world.  According to a 2018 report published by the Center for Managing Chronic Disease at the University of Michigan, more than 50% of the global population currently lives with

Oral Peptides and Proteins: The Growing Importance

Oral peptides and protein-based therapeutics have been in use for more than three decades since the approval of recombinant human insulin, the first protein therapy, in 1982. Earlier, most biologic drugs were the subcutaneous biologics. However, over time, advances in delivery formulations have enabled the development of oral peptides / proteins. Owing to numerous compelling

Pharma CMO: Current Market Landscape and Future Opportunities

 The present pipeline of pharmaceutical products is becoming increasingly complex and requires specialized facilities, equipment and operational expertise. In addition, the costs associated with acquiring manufacturing capabilities are exorbitant and, therefore, it is difficult for companies with limited finances and capacity constraints to succeed by themselves. Over the years, the pharmaceutical contract manufacturing (Pharma CMO)

Gene Therapies: Mapping the Future Growth Potential

The first gene therapy, Gendicine®, was only approved in 2003 in China; since then, the domain has evolved significantly. The ‘Gene Therapy Market (2nd Edition), 2018-2030’ report provides an extensive study on the current market landscape of gene therapies, with a prime focus on gene augmentation based therapies and oncolytic viral therapies, featuring an elaborate discussion on

Respiratory Disorders: Mapping the Future Potential

The World Health Organization (WHO) estimates the global prevalence of two of the most common chronic respiratory disorders, namely asthma and chronic obstructive pulmonary disease (COPD), to be around 335 million and 400 million patients respectively. According to the data provided by the WHO, more than 3 million people die annually from COPD. Asthma, on

Antibody Drug Conjugates: Riding on the Second Growth Wave

While there are close to 200 ADCs in various stages of development, the market field is currently going through a gradual transition, shifting from relying on conventional technologies to newer approaches for generating ADCs. The ‘Antibody Drug Conjugates Market (4th Edition), 2017-2030’ report provides a comprehensive study on the current landscape of ADCs, featuring an elaborate discussion

Microbiome Therapeutics and Diagnostics: Unlocking the Future Potential

Microbiome therapeutics represent a new frontier in the field of medicine. Currently, there are many probiotics, prebiotics, and medical foods and supplements that are commercially available, and several drug / therapy candidates that claim to be capable of modifying / manipulating the microbiome in order to provide therapeutic benefits. The ‘Microbiome Therapeutics and Diagnostics Market (2nd Edition), 2017-2030’ report provides a